Books > Medicine > Clinical & internal medicine
|
Buy Now
Pharma and Profits: Balancing Innovation, Medicine and Drug Prices (Paperback)
Loot Price: R524
Discovery Miles 5 240
|
|
Pharma and Profits: Balancing Innovation, Medicine and Drug Prices (Paperback)
(sign in to rate)
Loot Price R524
Discovery Miles 5 240
Expected to ship within 12 - 17 working days
|
High-level commentary on various facets of the pharmaceutical
industry from a key leader in the field This book clearly explains
the value that the pharmaceutical industry offers to society which
is often underreported against the more negative topic of high drug
prices. It also offers an overview for drug discovery and
development professionals, highlighting the challenges that such
drug hunters should be aware of when developing new drugs. Case
studies to illustrate topics like hepatitis C, mRNA vaccines,
insulin, and price controls are included to aid in seamless reader
comprehension. Written by John LaMattina, former president of
Pfizer Global Research and Development and well-known speaker and
writer for the pharma industry, sample topics covered and questions
explored within the work include: Fiscal consequences of curing
hepatitis C mRNA vaccines and the race for a cure Why the
government does not deserve a piece of Biopharma's profits Paying
for drugs whose ultimate value is unknown The impact of reduced
revenues on R&D This book is a must-read for biopharmaceutical
professionals and executives who wish to gain high-level insight
into key challenges that must be first understood, then overcome,
within the pharmaceutical industry.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.